Therapeutic potential of boosting NAD+ in aging and age-related diseases

Translational Medicine of Aging

Volumn 2, Issue , 2018, Pages 30-37

  Aman, Yahyah ^a   Qiu, Yumin ^b   Tao, Jun ^b   Fang, Evandro F ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

Age related diseases; Aging; Alzheimer's disease; Autophagy; NAD+; Neurodegeneration; Therapeutic potential

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE METHYLTRANSFERASE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE RIBOSIDE; PLACEBO;

AGE RELATED DISEASE; AGING; DEGENERATIVE DISEASE; DEPLETION; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GENE KNOCKDOWN; HUMAN; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE STRESS; PHYSICAL DISEASE BY DEVELOPMENTAL AGE; REVIEW;

EID: 85062112374     PISSN: None     EISSN: 24685011     Source Type: Journal    
DOI: 10.1016/j.tma.2018.08.003     Document Type: Review

References (95)

1. Canto, C., Menzies, K.J., Auwerx, J., NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metabol. 22 (2015), 31–53.
2. Magni, G., Amici, A., Emanuelli, M., Orsomando, G., Raffaelli, N., Ruggieri, S., Enzymology of NAD+ homeostasis in man. Cell. Mol. Life Sci. 61 (2004), 19–34.
3. Yaku, K., Okabe, K., Nakagawa, T., NAD metabolism: implications in aging and longevity. Ageing Res. Rev. 47 (2018), 1–17.
4. Verdin, E., NAD(+) in aging, metabolism, and neurodegeneration. Science 350 (2015), 1208–1213.
5. Yoshino, J., Baur, J.A., Imai, S.I., NAD(+) intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabol. 27 (2018), 513–528.
6. Misiak, M., Vergara Greeno, R., Baptiste, B.A., Sykora, P., Liu, D., Cordonnier, S., et al. DNA polymerase beta decrement triggers death of olfactory bulb cells and impairs olfaction in a mouse model of Alzheimer's disease. Aging Cell 16 (2017), 162–172.
7. Katsyuba, E., Auwerx, J., Modulating NAD(+) metabolism, from bench to bedside. EMBO J. 36 (2017), 2670–2683.
8. Rajman, L., Chwalek, K., Sinclair, D.A., Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabol. 27 (2018), 529–547.
9. Wallace, D.C., Mitochondria and cancer. Nat. Rev. Cancer 12 (2012), 685–698.
10. Fang, E.F., Lautrup, S., Hou, Y., Demarest, T.G., Croteau, D.L., Mattson, M.P., et al. NAD+ in aging: molecular mechanisms and translational implications. Trends Mol. Med. 23 (2017), 899–916.
11. Yoshino, J., Mills, K.F., Yoon, M.J., Imai, S., Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabol. 14 (2011), 528–536.
12. Peek, C.B., Affinati, A.H., Ramsey, K.M., Kuo, H.Y., Yu, W., Sena, L.A., et al. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science, 342, 2013, 1243417.
13. Stromsdorfer, K.L., Yamaguchi, S., Yoon, M.J., Moseley, A.C., Franczyk, M.P., Kelly, S.C., et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16 (2016), 1851–1860.
14. Karamanlidis, G., Lee, C.F., Garcia-Menendez, L., Kolwicz, S.C. Jr., Suthammarak, W., Gong, G., et al. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metabol. 18 (2013), 239–250.
15. Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155 (2013), 1624–1638.
16. Guan, Y., Wang, S.R., Huang, X.Z., Xie, Q.H., Xu, Y.Y., Shang, D., et al. Nicotinamide mononucleotide, an NAD(+) precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J. Am. Soc. Nephrol. 28 (2017), 2337–2352.
17. North, B.J., Rosenberg, M.A., Jeganathan, K.B., Hafner, A.V., Michan, S., Dai, J., et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 33 (2014), 1438–1453.
18. Lin, J.B., Kubota, S., Ban, N., Yoshida, M., Santeford, A., Sene, A., et al. NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice. Cell Rep. 17 (2016), 69–85.
19. de Picciotto, N.E., Gano, L.B., Johnson, L.C., Martens, C.R., Sindler, A.L., Mills, K.F., et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15 (2016), 522–530.
20. Stein, L.R., Imai, S., Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 33 (2014), 1321–1340.
21. Yoon, M.J., Yoshida, M., Johnson, S., Takikawa, A., Usui, I., Tobe, K., et al. SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD+ and function in mice. Cell Metabol. 21 (2015), 706–717.
22. Mills, K.F., Yoshida, S., Stein, L.R., Grozio, A., Kubota, S., Sasaki, Y., et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabol. 24 (2016), 795–806.
23. Jadeja, R.N., Powell, F.L., Jones, M.A., Fuller, J., Joseph, E., Thounaojam, M.C., et al. Loss of NAMPT in aging retinal pigment epithelium reduces NAD(+) availability and promotes cellular senescence. Aging (Albany NY) 10:6 (2018), 1306–1323.
24. Caton, P.W., Kieswich, J., Yaqoob, M.M., Holness, M.J., Sugden, M.C., Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia 54 (2011), 3083–3092.
25. Ramsey, K.M., Mills, K.F., Satoh, A., Imai, S., Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7 (2008), 78–88.
26. Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabol. 6 (2007), 363–375.
27. Gulshan, M., Yaku, K., Okabe, K., Mahmood, A., Sasaki, T., Yamamoto, M., et al. Overexpression of Nmnat3 efficiently increases NAD and NGD levels and ameliorates age-associated insulin resistance. Aging Cell, 2018, e12798.
28. Yamamoto, T., Byun, J., Zhai, P., Ikeda, Y., Oka, S., Sadoshima, J., Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One, 9, 2014, e98972.
29. Park, J.H., Long, A., Owens, K., Kristian, T., Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol. Dis. 95 (2016), 102–110.
30. Long, A.N., Owens, K., Schlappal, A.E., Kristian, T., Fishman, P.S., Schuh, R.A., Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol., 15, 2015, 19.
31. Wang, X., Hu, X., Yang, Y., Takata, T., Sakurai, T., Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 1643 (2016), 1–9.
32. Yao, Z., Yang, W., Gao, Z., Jia, P., Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 647 (2017), 133–140.
33. Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T., Nilsen, H., et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157 (2014), 882–896.
34. Fang, E.F., Kassahun, H., Croteau, D.L., Scheibye-Knudsen, M., Marosi, K., Lu, H., et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metabol. 24 (2016), 566–581.
35. Fang, E.F., Bohr, V.A., NAD+: the convergence of DNA repair and mitophagy. Autophagy 13 (2017), 442–443.
36. Poljsak, B., Milisav, I., NAD+ as the link between oxidative stress, inflammation, caloric restriction, exercise, DNA repair, longevity, and health span. Rejuvenation Res. 19:5 (2016), 406–413.
37. Belenky, P., Racette, F.G., Bogan, K.L., McClure, J.M., Smith, J.S., Brenner, C., Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129 (2007), 473–484.
38. Lu, S.P., Kato, M., Lin, S.J., Assimilation of endogenous nicotinamide riboside is essential for calorie restriction-mediated life span extension in Saccharomyces cerevisiae. J. Biol. Chem. 284 (2009), 17110–17119.
39. Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto, C., et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154 (2013), 430–441.
40. Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352 (2016), 1436–1443.
41. Tsang, F., James, C., Kato, M., Myers, V., Ilyas, I., Tsang, M., et al. Reduced Ssy1-Ptr3-Ssy5 (SPS) signaling extends replicative life span by enhancing NAD+ homeostasis in Saccharomyces cerevisiae. J. Biol. Chem. 290 (2015), 12753–12764.
42. Canto, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metabol. 15 (2012), 838–847.
43. Xu, W., Barrientos, T., Mao, L., Rockman, H.A., Sauve, A.A., Andrews, N.C., Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 13 (2015), 533–545.
44. Trammell, S.A., Weidemann, B.J., Chadda, A., Yorek, M.S., Holmes, A., Coppey, L.J., et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci. Rep., 6, 2016, 26933.
45. Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R., et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63 (2016), 1190–1204.
46. Zhou, C.C., Yang, X., Hua, X., Liu, J., Fan, M.B., Li, G.Q., et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br. J. Pharmacol. 173 (2016), 2352–2368.
47. Ryu, D., Zhang, H., Ropelle, E.R., Sorrentino, V., Mazala, D.A., Mouchiroud, L., et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med., 8, 2016, 361ra139.
48. Frederick, D.W., Loro, E., Liu, L., Davila, A. Jr., Chellappa, K., Silverman, I.M., et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metabol. 24 (2016), 269–282.
49. Schondorf, D.C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson's disease. Cell Rep. 23 (2018), 2976–2988.
50. Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 34 (2013), 1581–1588.
51. Hou, Y., Lautrup, S., Cordonnier, S., Wang, Y., Croteau, D.L., Zavala, E., et al. NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl. Acad. Sci. U. S. A. 115 (2018), E1876–E1885.
52. Sorrentino, V., Romani, M., Mouchiroud, L., Beck, J.S., Zhang, H., D'Amico, D., et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature 552 (2017), 187–193.
53. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361 (2009), 1651–1661.
54. Scheibye-Knudsen, M., Mitchell, S.J., Fang, E.F., Iyama, T., Ward, T., Wang, J., et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metabol. 20 (2014), 840–855.
55. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M., Sinclair, D.A., Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277 (2002), 45099–45107.
56. Gallo, C.M., Smith, D.L. Jr., Smith, J.S., Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol. Cell Biol. 24 (2004), 1301–1312.
57. Schmeisser, K., Mansfeld, J., Kuhlow, D., Weimer, S., Priebe, S., Heiland, I., et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 9 (2013), 693–700.
58. van der Horst, A., Schavemaker, J.M., Pellis-van Berkel, W., Burgering, B.M., The Caenorhabditis elegans nicotinamidase PNC-1 enhances survival. Mech. Ageing Dev. 128 (2007), 346–349.
59. Mitchell, S.J., Bernier, M., Aon, M.A., Cortassa, S., Kim, E.Y., Fang, E.F., et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. Cell Metabol. 27 (2018), 667–676 e4.
60. Williams, P.A., Harder, J.M., Foxworth, N.E., Cochran, K.E., Philip, V.M., Porciatti, V., et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355 (2017), 756–760.
61. Morales, J., Li, L., Fattah, F.J., Dong, Y., Bey, E.A., Patel, M., et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev. Eukaryot. Gene Expr. 24 (2014), 15–28.
62. Bai, P., Canto, C., Oudart, H., Brunyanszki, A., Cen, Y., Thomas, C., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabol. 13 (2011), 461–468.
63. Martire, S., Fuso, A., Rotili, D., Tempera, I., Giordano, C., De Zottis, I., et al. PARP-1 modulates amyloid beta peptide-induced neuronal damage. PLoS One, 8, 2013, e72169.
64. Cosi, C., Chopin, P., Marien, M., Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. 735 (1996), 343–348.
65. Wu, X.L., Wang, P., Liu, Y.H., Xue, Y.X., Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease. J. Mol. Neurosci. 53 (2014), 1–9.
66. Kauppinen, T.M., Suh, S.W., Higashi, Y., Berman, A.E., Escartin, C., Won, S.J., et al. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J. Neuroinflamm., 8, 2011, 152.
67. Mandir, A.S., Przedborski, S., Jackson-Lewis, V., Wang, Z.Q., Simbulan-Rosenthal, C.M., Smulson, M.E., et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl. Acad. Sci. U. S. A. 96 (1999), 5774–5779.
68. Yokoyama, H., Kuroiwa, H., Tsukada, T., Uchida, H., Kato, H., Araki, T., Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J. Neurosci. Res. 88 (2010), 1522–1536.
69. Kim, T.W., Cho, H.M., Choi, S.Y., Suguira, Y., Hayasaka, T., Setou, M., et al. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. Cell Death Dis., 4, 2013, e919.
70. Chini, E.N., CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr. Pharmaceut. Des. 15 (2009), 57–63.
71. Aksoy, P., White, T.A., Thompson, M., Chini, E.N., Regulation of intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. Res. Commun. 345 (2006), 1386–1392.
72. Barbosa, M.T., Soares, S.M., Novak, C.M., Sinclair, D., Levine, J.A., Aksoy, P., et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21 (2007), 3629–3639.
73. Adebanjo, O.A., Anandatheerthavarada, H.K., Koval, A.P., Moonga, B.S., Biswas, G., Sun, L., et al. A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis. Nat. Cell Biol. 1 (1999), 409–414.
74. Scheibye-Knudsen, M., Tseng, A., Borch Jensen, M., Scheibye-Alsing, K., Fang, E.F., Iyama, T., et al. Cockayne syndrome group A and B proteins converge on transcription-linked resolution of non-B DNA. Proc Natl. Acad. Sci. U. S. A. 113 (2016), 12502–12507.
75. Escande, C., Nin, V., Price, N.L., Capellini, V., Gomes, A.P., Barbosa, M.T., et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62 (2013), 1084–1093.
76. Jin, D., Liu, H.X., Hirai, H., Torashima, T., Nagai, T., Lopatina, O., et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446 (2007), 41–45.
77. Hayakawa, K., Esposito, E., Wang, X., Terasaki, Y., Liu, Y., Xing, C., et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature 535 (2016), 551–555.
78. Camacho-Pereira, J., Tarrago, M.G., Chini, C.C.S., Nin, V., Escande, C., Warner, G.M., et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabol. 23 (2016), 1127–1139.
79. Blacher, E., Dadali, T., Bespalko, A., Haupenthal, V.J., Grimm, M.O., Hartmann, T., et al. Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 78 (2015), 88–103.
80. Pissios, P., Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends Endocrinol. Metabol. 28 (2017), 340–353.
81. Liu, M., Li, L., Chu, J., Zhu, B., Zhang, Q., Yin, X., et al. Serum N(1)-methylnicotinamide is associated with obesity and diabetes in Chinese. J Clin. Endocrinol. Metabol. 100 (2015), 3112–3117.
82. Kannt, A., Pfenninger, A., Teichert, L., Tonjes, A., Dietrich, A., Schon, M.R., et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 58 (2015), 799–808.
83. Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T., et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508 (2014), 258–262.
84. Kannt, A., Rajagopal, S., Kadnur, S.V., Suresh, J., Bhamidipati, R.K., Swaminathan, S., et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci. Rep., 8, 2018, 3660.
85. Titov, D.V., Cracan, V., Goodman, R.P., Peng, J., Grabarek, Z., Mootha, V.K., Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science 352 (2016), 231–235.
86. Cracan, V., Titov, D.V., Shen, H., Grabarek, Z., Mootha, V.K., A genetically encoded tool for manipulation of NADP(+)/NADPH in living cells. Nat. Chem. Biol. 13 (2017), 1088–1095.
87. Cambronne, X.A., Stewart, M.L., Kim, D., Jones-Brunette, A.M., Morgan, R.K., Farrens, D.L., et al. Biosensor reveals multiple sources for mitochondrial NAD(+). Science 352 (2016), 1474–1477.
88. Zhao, Y., Hu, Q., Cheng, F., Su, N., Wang, A., Zou, Y., et al. SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metabol. 21 (2015), 777–789.
89. Liu, L., Su, X., Quinn, W.J. 3rd, Hui, S., Krukenberg, K., Frederick, D.W., et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metabol. 27 (2018), 1067–10680 e5.
90. Trammell, S.A., Schmidt, M.S., Weidemann, B.J., Redpath, P., Jaksch, F., Dellinger, R.W., et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun., 7, 2016, 12948.
91. Dellinger, R.W., Santos, S.R., Morris, M., Evans, M., Alminana, D., Guarente, L., et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech. Dis., 3, 2017, 17.
92. Martens, C.R., Denman, B.A., Mazzo, M.R., Armstrong, M.L., Reisdorph, N., McQueen, M.B., et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat. Commun., 9, 2018, 1286.
93. Chini, C.C., Guerrico, A.M., Nin, V., Camacho-Pereira, J., Escande, C., Barbosa, M.T., et al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin. Cancer Res. 20 (2014), 120–130.
94. Ju, H.Q., Zhuang, Z.N., Li, H., Tian, T., Lu, Y.X., Fan, X.Q., et al. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 379 (2016), 1–11.
95. Fivenson, E.M., Lautrup, S., Sun, N., Scheibye-Knudsen, M., Stevnsner, T., Nilsen, H., et al. Mitophagy in neurodegeneration and aging. Neurochem. Int. 109 (2017), 202–209.